Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy

Kidney International

Volumn 64, Issue 3, 2003, Pages 1050-1058

  Narita, Ichiei ^a   Goto, Shin ^a   Saito, Noriko ^a   Song, Jin ^a   Omori, Kentaro ^a   Kondo, Daisuke ^a   Sakatsume, Minoru ^a   Gejyo, Fumitake ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Angiotensinogen; Gene polymorphism; IgA nephropathy; Renal survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CANDESARTAN; CAPTOPRIL; CORTICOSTEROID; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ENALAPRIL; IMMUNOGLOBULIN A; LISINOPRIL; LOSARTAN; PROTEIN; QUINAPRIL; TEMOCAPRIL;

ADULT; AGT GENE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL FEATURE; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULONEPHRITIS; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL;

EID: 0042431977     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00187.x     Document Type: Article

References (38)

1. LEVY M, BERGER J: Worldwide perspective of IgA nephropathy. Am J Kidney Dis 12:340-347, 1988
2. KOYAMA A, IGARASHI M, KOBAYASHI M: Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis 29:526-532, 1997
3. GALLA JH: IgA nephropathy. Kidney Int 47:377-387, 1995
4. SZETO CC, LAI FM, TO KF, et al: The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 110:434-437, 2001
5. SCOLARI F, AMOROSO A, SAVOLDI S, et al: Familial clustering of IgA nephropathy: Further evidence in an Italian population. Am J Kidney Dis 33:857-865, 1999
6. HSU SI, RAMIREZ SB, WINN MP, et al: Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 57:1818-1835, 2000
7. REMUZZI A, PERICO N, SANGALLI F, et al: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276:F457-F466, 1999
8. HILGERS KF, MANN JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 13:1100-1108, 2002
9. WOO KT, LAU YK, WONG KS, et al: ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 58:2485-2491, 2000
10. RIGAT B, HUBERT C, ALHENC-GELAS F, et al: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
11. TIRET L, RIGAT B, VISVIKIS S, et al: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 51:197-205, 1992
12. YOSHIDA H, MITARAI T, KAWAMURA T, et al: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96:2162-2169, 1995
13. MORIYAMA T, KITAMURA H, OCHI S, et al: Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 6:1676-1678, 1995
14. VAN ESSEN GG, RENSMA PL, DE ZEEUW D, et al: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347:94-95, 1996
15. PARVING HH, JACOBSEN P, TARNOW L, et al: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study. Br Med J 313:591-594, 1996
16. PENNO G, CHATURVEDI N, TALMUD PJ, et al: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47:1507-1511, 1998
17. YANAI K, SAITO T, HIROTA K, et al: Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity. J Biol Chem 272:30558-30562, 1997
18. ZHAO YY, ZHOU J, NARAYANAN CS, et al: Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension 33:108-115, 1999
19. SCHMIDT S, SHARMA AM, ZILCH O, et al: Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset, Nephrol Dial Transplant 10:1145-1148, 1995
20. ISHIGAMI T, UMEMURA S, TAMURA K, et al: Essential hypertension and 5′ upstream core promoter region of human angiotensinogen gene. Hypertension 30:1325-1330, 1997
21. THOMPSON EA, DEEB S, WALKER D, et al: The detection of linkage disequilibrium between closely linked markers: RFLPs at the AI-CIII apolipoprotein genes. Am J Hum Genet 42:113-124, 1988
22. ISHIGAMI T, TAMURA K, EUJITA T, et al: Angiotensinogen gene polymorphism near transcription start site and blood pressure: Role of a T-to-C transition at intron I. Hypertension 34:430-434, 1999
23. NAKAJIMA T, JORDE LB, ISHIGAMI T, et al: Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations. Am J Hum Genet 70:108-123, 2002
24. JEUNEMAITRE X, SOUBRIER F, KOTELEVTSEV YV, et al: Molecular basis of human hypertension: Role of angiotensinogen. Cell 71:169-180, 1992
25. KATO N, SUGIYAMA T, MORITA H, et al: Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and meta-analysis on six reported studies. J Hypertens 17:757-763, 1999
26. SATO N, KATSUYA T, NAKAGAWA T, et al: Nine polymorphisms of angiotensinogen gene in the susceptibility to essential hypertension. Life Sci 68:259-272, 2000
27. SATO N, KATSUYA T, RAKUGI H, et al: Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hypertension 30:321-325, 1997
28. GOTO S, NARITA I, SAITO N, et al: A(-20)C polymorphism of the angiotensinogen gene and progression of IgA nephropathy. Kidney Int 62:980-985, 2002
29. PEI Y, SCHOLEY J, THAI K, et al: Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 100:814-820, 1997
30. INOUE I, NAKAJIMA T, WILLIAMS CS, et al: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786-1797, 1997
31. MARTIN ER, LAI EH, GILBERT JR, et al: SNPing away at complex diseases: Analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 67:383-394, 2000
32. LEWIS EJ, HUNSICKER LG, BAIN RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
33. GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45:861-867, 1994
34. GAINER JV, MORROW JD, LOVELAND A, et al: Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292, 1998
35. RUSSO D, PISANI A, BALLETTA MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
36. RUSSO D, MINUTOLO R, PISANI A, et al: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18-25, 2001
37. RUILOPE LM, ALDIGIER JC, PONTICELLI C, et al: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89-95, 2000
38. MOGENSEN CE, NELDAM S, TIKKANEN I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 321:1440-1444, 2000